

14 May 2018

Mr Ron Kaushik  
Compliance and Surveillance Manager  
National Stock Exchange of Australia  
1 Bligh Street  
Sydney NSW 2000

By email: ron.kaushik@nsx.com.au

Dear Mr. Kaushik,

### **Beroni Group Limited (Company) – Price Query**

We refer to your letter dated 14 May 2018.

Our response to your queries are as follows:

1. No. The Company is not aware of any other information concerning it, that has not been announced to the market and which, if known, could be reasonably regarded as an explanation for recent trading in the securities of the Company.
2. Not applicable.
3. Over the past few months the Company has signed a sponsored research agreement with the Columbia University, a term sheet with UNSW to proceed to Stage 2 of anti-cancer drug PENAO, and the investment into Dendrix (an immune cell therapy company based in Tokyo, Japan). The Company is of the opinion that investors continue to provide support based on the Company's strategy to focus on biotechnology, life sciences, environmental science and governance, precision medicine, regenerative medicine, and stem cell anti-cancer and anti-aging projects.
4. The Company is in compliance with the listing rules and, in particular, listing rule 6.4.

Yours sincerely,

For and On Behalf of the Board of Beroni Group Limited

BoQing Zhang  
Executive Chairman